Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.33 |
| ▸ | POLRMT | O00411 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120838 | 0.88 | TNK2 (0.35) | TNK2RIPK1POLRMT | |
| SCHEMBL17719386 | 0.88 | TNK2 (0.35) | TNK2RIPK1POLRMT | |
| SCHEMBL18371662 | 0.88 | TNK2 (0.35) | TNK2RIPK1POLRMT | |
| SCHEMBL10120675 | 0.88 | TNK2 (0.35) | TNK2RIPK1POLRMT | |
| SCHEMBL10120857 | 0.86 | TNK2 (0.33) | TNK2RIPK1 | |
| SCHEMBL13532039 | 0.85 | TNK2 (0.33) | TNK2RIPK1POLRMT | |
| SCHEMBL10120843 | 0.83 | RIPK1 (0.31) | TNK2RIPK1 | |
| SCHEMBL17719377 | 0.83 | RIPK1 (0.31) | TNK2RIPK1 | |
| SCHEMBL10120684 | 0.83 | TMPRSS2 (0.35) | TNK2RIPK1 | |
| SCHEMBL17719232 | 0.83 | TMPRSS2 (0.35) | TNK2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| US-8853171-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130034521-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034521-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | TNK2 1494/4885RIPK1 821/4885POLRMT 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.